Insmed (INSM) traded lower in the latest session, down roughly 6% to $136.26, as investors continued to digest the company’s April 7, 2026 disclosure that the Phase 2b CEDAR trial of brensocatib in hidradenitis suppurativa (HS) failed to meet both primary and secondary efficacy endpoints in the 10 mg and 40 mg arms. The company said it would discontinue development of brensocatib for HS, removing a potential growth option and reviving questions about how much of Insmed’s valuation was tied to pipeline expansion beyond its lead commercial franchise. (investor.insmed.com)

Even though the HS setback was announced earlier in April, follow-through selling has continued as investors recalibrate probability-weighted pipeline value and reassess near-term positioning. Market chatter has also focused on elevated bearish positioning and volatility risk into upcoming catalysts, which can magnify moves on days with limited fresh company-specific headlines. (marketbeat.com)

Near term, attention is shifting to the company’s next earnings update; third-party calendars list an estimated earnings date around late April or early May 2026 (the company has not confirmed a date in those listings). Investors will be watching for updates on commercial trajectory, expense discipline, and the timing of key clinical data readouts that could reset sentiment after the HS discontinuation. (marketbeat.com)